**Dave Lashmet**

Individual microeconomics may not matter, but collectively they do matter.

There’s a feedback loop in muscles – use it or lose it (atrophy). Musclin helps you exercise. Without exercise, you will become overweight – there’s no muscular benefit to weighing twice as much. Obesity rates have risen steadily over the past decade. This isn’t one person’s problem – it’s everyone’s problem.

We now have the technology that anyone can easily cut weight in months or years. Novo Nordisk’s (NVO) obesity drugs – Ozempic and Wegovy – is the new Hollywood “it drug.” People who received Ozempic in a trial lose 17% of their weight.

Eli Lilly (LLY) has a new competing drug, where people lost 22% of their weight in trial. Dave likes Novo Nordisk’s drugs better than Eli Lilly, since it comes in pill form versus injection. The pills are going to be in mass demand – there are 100 million obese Americans.

The While these drugs help lose weight, they do not change how obesity hits your liver. Excess fat and scar tissue in the liver leads to failure. There is no dialysis for livers – only liver transplants. End stage of liver disease is usually death.

Madrigal (MDGL) bought rights to a chlorine fake iodine which can remove fats and scar tissue in the liver. In a once a day pill, this goes alongside the weight-loss pills. It’s running clinical trials, which show the drug works in trials. They will get bought out – likely by Novo Nordisk or Eli Lilly. There is a rival pill – from Inventiva (IVA), which has also shown progress in Phase 2 trials.

Novo Nordisk will be the winner in the weight-loss and fatty liver disease market.

Exercise is key to keeping weight off once (if) you stop taking the appetite suppressing drug. Working out will rejuvenate your heart. Fitness trackers are a good start to watching your output. Not only will this keep weight off, but it will improve underlying health.

Novo Nordisk has an Alzheimer’s drug that has jumped straight through to Phase 3 trials. It could end up being a once-daily Alzheimer’s treatment.

The three buys from this presentation: Novo Nordisk (NVO), Madrigal (MDGL), and Inventiva (IVA).